



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 10, 2013 6:00 – 8:30 p.m.

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:40**
 - Updates
 - DUR Board Schedule for 2014

- 4. Medical Director Update** **6:40 - 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:45 – 6:50**
 - Buprenorphine and Opiates

- 6. RetroDUR/DUR** **6:50 – 7:30**
 - Opiate Analgesics: Review of Clinical Guidelines and Summary of Edits/Approaches from other State Medicaid Programs

- 7. Clinical Update: Drug Reviews** **7:30 – 7:55**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Desvenlafaxine[®] 24 hr Oral Tablet
 - Forfivo[®] XL (bupropion) Extended Release Oral Tablet
 - Lyrica[®] (pregabalin) Oral Solution
 - Prolensa[®] (bromfenac 0.07 %) Ophthalmic Solution
 - Simbrinza[®] (brinzolamide 1 %/ brimonidine 0.2 %) Ophthalmic Suspension
 - Zenedi[®] (dextroamphetamine) Oral Tablet

 - Full New Drug Reviews**
 - Lipruzet[®] (ezetimibe/atorvastatin) Oral Tablet

- 8. Clinical Update: New/Updated Clinical Guidelines** **7:25 – 7:55**
(Public comment prior to Board action)
- New Cholesterol Treatment Guidelines Released
- 9. Therapeutic Drug Classes – Periodic Review** **7:55 – 8:15**
(Public comment prior to Board action)
Class review documents available on DVHA web site 12/10/2013 @ Noon
- Acne Medications: Topical
 - Anti-hypertensives: Angiotensin Converting Enzyme (ACE) Inhibitors and Combinations
 - Anti-hypertensives: Angiotensin Receptor Blockers and Combinations
 - Gastrointestinal: H2 Receptor Antagonists
 - Otic: Anti-Infectives
 - Renal: Phosphate Binders
- 10. New Managed Therapeutic Drug Classes** **8:15– 8:15**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:15 – 8:25**
(Public comment prior to Board action)
- Anti-infectives: Antivirals: Influenza Vaccines
 - Ilaris[®] (canakinumab) Injection in SIJA (new FDA approved diagnosis)
 - Makena[®] (hydroxyprogesterone) Injection
- 12. General Announcements** **8:25– 8:30**
Selected FDA Safety Alerts
- Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
 - Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
 - Rosiglitazone – FDA lifts prescribing restrictions
 - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection
- 13. Adjourn** **8:30**